CRISPR/Cas9 as a Novel Gene Therapy Tool for Dominantly Inherited Forms of Neurodegenerative Disorders

Time: 12:00 pm
day: Day Two: Track A AM

Details:

  • Cell model based assessment of CRISPR/Cas9 as treatment of familial Alzheimer’s disease and Parkinson’s disease
  • Mouse model based assessment of CRISPR/Cas9 as treatment of familial Alzheimer’s disease and Parkinson’s disease
  • Challenges ahead before CRISPR/Cas9 can be assessed in clinical trials on patients with neurodegenerative disorders

Speakers: